Thalidomide in Crohn disease [5]

Journal of Pediatric Gastroenterology and Nutrition

Volumn 40, Issue 2, 2005, Pages 236-

  Pigott, A ^a   Casson, D ^a  

^a ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

METRONIDAZOLE; THALIDOMIDE;

CHILD; CROHN DISEASE; HUMAN; LETTER; MUSCLE WEAKNESS; NERVE CONDUCTION; NERVOUS SYSTEM INJURY; NEUROLOGIC EXAMINATION; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; TREATMENT OUTCOME;

CLINICAL TRIALS; CROHN DISEASE; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PERIPHERAL NERVOUS SYSTEM DISEASES; SENSITIVITY AND SPECIFICITY; THALIDOMIDE;

EID: 19744382754     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200502000-00035     Document Type: Letter

References (4)

1. Ahmed M, El-Hadi S, Jenkins HR. Thalidomide in Crohn's disease and the risk of peripheral neuropathy. J Pediatr Gastroenterol Nutr 2003;37:522.
2. Ehrenpries ED, Sunada VK, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open label trial. Gastroenterology 1999;117:1271-7.
3. Molloy FM, Floeter MK, Syed NA, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001;24:1050-7.
4. Chaudhry V, Cornblath DR, Corse A, Friemer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872-5.